Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Urothelial Cancer | Research article

Genomic profiling of Chinese patients with urothelial carcinoma

Authors: Bo Yang, Xiao Zhao, Chong Wan, Xin Ma, Shaoxi Niu, Aitao Guo, Jieli Wang, Jinliang Wang, Decong Sun, Shunchang Jiao

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Backgrounds

Urothelial carcinoma (UC) is the most common genitourinary malignancy in China. In this study, we surveyed the genomic features in Chinese UC patients and investigated the concordance of genetic alterations between circulating tumor DNA (ctDNA) in plasma and matched tumor tissue.

Materials and methods

A total of 112 UC patients were enrolled, of which 31 were upper tract UC (UTUC) and 81 were UC of bladder (UCB). Genomic alterations in 92 selected genes were analyzed by targeted next-generation sequencing.

Results

In the study cohort, 94.64, 86.61 and 62.50% of patients were identified as having valid somatic, oncogenic and actionable somatic alterations, respectively. The most frequently altered genes included TP53, KMT2D, KDM6A, FAT4, FAT1, CREBBP and ARID1A. The higher prevalence of HRAS (22.0% vs 3.7%) and KMT2D (59.26% vs 34.57%) was identified in UTUC than in UCB. Comparisons of somatic alterations of UCB and UTUC between the study cohort and western cohorts revealed significant differences in mutant prevalence. Notably, 28.57, 17.86 and 47.32% of the cases harbored alterations in FGFRs, ERBBs and DNA damage repair genes, respectively. Furthermore, 75% of the patients carried non-benign germline variants, but only two (1.79%) were pathogenic. The overall concordance for genomic alterations in ctDNA and matched tumor tissue was 42.97% (0–100%). Notably, 47.25% of alterations detected in ctDNA were not detected in the matched tissue, and 54.14% of which were oncogenic mutations.

Conclusions

We found a unique genomic feature of Chinese UC patients. A reasonably good concordance of genomic features between ctDNA and tissue samples were identified.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef
3.
go back to reference Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (tat1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76:639–57.CrossRef Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (tat1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76:639–57.CrossRef
4.
go back to reference Network T. C. G. A. R. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.CrossRef Network T. C. G. A. R. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.CrossRef
5.
go back to reference Xiong G, Chen X, Li X, et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. 2014;113:521–6.CrossRef Xiong G, Chen X, Li X, et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. 2014;113:521–6.CrossRef
6.
go back to reference Birkenkamp-Demtroder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73:535–40.CrossRef Birkenkamp-Demtroder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73:535–40.CrossRef
7.
go back to reference Chakravarty D, Gao J, Phillips S, et al. Oncokb: a precision oncology knowledge base. JCO Precis Oncol. 2017:1–16. Chakravarty D, Gao J, Phillips S, et al. Oncokb: a precision oncology knowledge base. JCO Precis Oncol. 2017:1–16.
8.
go back to reference Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from pd-1/pd-l1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685–94.CrossRef Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from pd-1/pd-l1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685–94.CrossRef
9.
go back to reference Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8:444–57.CrossRef Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8:444–57.CrossRef
10.
go back to reference Pang C, Guan Y, Li H, et al. Urologic cancer in China. Jpn J Clin Oncol. 2016;46:497–501.CrossRef Pang C, Guan Y, Li H, et al. Urologic cancer in China. Jpn J Clin Oncol. 2016;46:497–501.CrossRef
11.
go back to reference Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–48.CrossRef Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–48.CrossRef
12.
go back to reference Kim WY, Rose TL, Roghmann F, et al. Predictive value of fibroblast growth factor receptor (fgfr) alterations on anti-pd-(l)1 treatment outcomes in patients (pts) with advanced urothelial cancer (uc): Pooled analysis of real-world data. Journal. 2020;38:493. Kim WY, Rose TL, Roghmann F, et al. Predictive value of fibroblast growth factor receptor (fgfr) alterations on anti-pd-(l)1 treatment outcomes in patients (pts) with advanced urothelial cancer (uc): Pooled analysis of real-world data. Journal. 2020;38:493.
13.
go back to reference Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary t-cell depleted contexture and activated fgfr3 signaling. Nat Commun. 2019;10:2977.CrossRef Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary t-cell depleted contexture and activated fgfr3 signaling. Nat Commun. 2019;10:2977.CrossRef
14.
go back to reference Yan M, Schwaederle M, Arguello D, et al. Her2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.CrossRef Yan M, Schwaederle M, Arguello D, et al. Her2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.CrossRef
15.
go back to reference Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. Erbb2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384–8.CrossRef Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. Erbb2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384–8.CrossRef
16.
go back to reference Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase ii national cancer institute trial. J Clin Oncol. 2007;25:2218–24.CrossRef Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase ii national cancer institute trial. J Clin Oncol. 2007;25:2218–24.CrossRef
17.
go back to reference Oh DY, Bang YJ. Her2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48.CrossRef Oh DY, Bang YJ. Her2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48.CrossRef
18.
go back to reference Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68:959–67.CrossRef Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68:959–67.CrossRef
19.
go back to reference Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis. Oncol. 2018;2:1–13. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis. Oncol. 2018;2:1–13.
20.
go back to reference Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (toparp-b): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74.CrossRef Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (toparp-b): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74.CrossRef
21.
go back to reference Powles TB, Balar A, Gravis G, et al. An adaptive, biomarker directed platform study in metastatic urothelial cancer (Biscay) with durvalumab in combination with targeted therapies. Ann Oncol. 2019;30:v356–402.CrossRef Powles TB, Balar A, Gravis G, et al. An adaptive, biomarker directed platform study in metastatic urothelial cancer (Biscay) with durvalumab in combination with targeted therapies. Ann Oncol. 2019;30:v356–402.CrossRef
22.
go back to reference Carlo MI, Ravichandran V, Srinavasan P, et al. Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol. 2020;38:406–14.CrossRef Carlo MI, Ravichandran V, Srinavasan P, et al. Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol. 2020;38:406–14.CrossRef
23.
go back to reference Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ercc4, encoding the DNA-repair endonuclease xpf, cause fanconi anemia. Am J Hum Genet. 2013;92:800–6.CrossRef Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ercc4, encoding the DNA-repair endonuclease xpf, cause fanconi anemia. Am J Hum Genet. 2013;92:800–6.CrossRef
24.
go back to reference Consortium APG. Aacr project genie: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818–31.CrossRef Consortium APG. Aacr project genie: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818–31.CrossRef
25.
go back to reference Harper HL, McKenney JK, Heald B, et al. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol. 2017;30:146–56.CrossRef Harper HL, McKenney JK, Heald B, et al. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol. 2017;30:146–56.CrossRef
26.
go back to reference Mork M, Hubosky SG, Roupret M, et al. Lynch syndrome: a primer for urologists and panel recommendations. J Urol. 2015;194:21–9.CrossRef Mork M, Hubosky SG, Roupret M, et al. Lynch syndrome: a primer for urologists and panel recommendations. J Urol. 2015;194:21–9.CrossRef
27.
go back to reference Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–57.CrossRef Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–57.CrossRef
28.
go back to reference Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020;17(5):271–91.CrossRef Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020;17(5):271–91.CrossRef
29.
go back to reference Barata PC, Koshkin VS, Funchain P, et al. Next-generation sequencing (ngs) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017;28:2458–63.CrossRef Barata PC, Koshkin VS, Funchain P, et al. Next-generation sequencing (ngs) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017;28:2458–63.CrossRef
30.
go back to reference Agarwal N, Pal SK, Hahn AW, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018;124:2115–24.CrossRef Agarwal N, Pal SK, Hahn AW, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018;124:2115–24.CrossRef
Metadata
Title
Genomic profiling of Chinese patients with urothelial carcinoma
Authors
Bo Yang
Xiao Zhao
Chong Wan
Xin Ma
Shaoxi Niu
Aitao Guo
Jieli Wang
Jinliang Wang
Decong Sun
Shunchang Jiao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07829-1

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine